Physician profile
Gregory Ackroyd
NPI 1538192984
$3,191.52
in general payments reported to CMS, 2019-2025
19 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $311 · 2021: $491 · 2022: $482 · 2023: $501 · 2024: $583 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.88 |
| Education | $191.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $1,048.92 | 2019-2025 | (Di2) Nasal Masks - Over The Head, (6299) Dreamwear, Nasal Masks - Over The Head |
| Jazz Pharmaceuticals INC. | $543.44 | 2019-2024 | |
| Glaxosmithkline, LLC. | $390.45 | 2019-2024 | Nucala |
| Itamar Medical INC | $295.08 | 2021-2024 | Watchpatone |
| Avadel Cns Pharmaceuticals, LLC | $149.97 | 2024-2025 | Lumryz |
| Harmony Biosciences LLC | $143.11 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $131.79 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.99 | 2024 | Ofev |
| Genzyme Corporation | $62.28 | 2023-2024 | |
| Baxter Healthcare | $61.58 | 2023-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Astrazeneca Pharmaceuticals Lp | $49.70 | 2021-2024 | Airsupra |
| Resmed Corp | $46.87 | 2020-2021 | |
| Axsome Therapeutics, INC. | $36.83 | 2023-2025 | Sunosi |
| Fisher & Paykel Healthcare INC | $35.38 | 2022 | |
| Inspire Medical Systems, INC. | $32.40 | 2025 | Inspire |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $31.11 | 2023 | Glassia |
| Lilly USA, LLC | $19.06 | 2025 | Zepbound |
| Zoll Respicardia, INC. | $17.21 | 2025 | Remede System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $4.35 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Ackroyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.